Business Description
Aequus Pharmaceuticals Inc
NAICS : 325412
SIC : 3741
ISIN : CA0076361033
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -7.25 | |||||
Debt-to-Equity | -1.05 | |||||
Debt-to-EBITDA | -2.83 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -74.19 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -58.5 | |||||
3-Year EBITDA Growth Rate | -88.2 | |||||
3-Year EPS without NRI Growth Rate | -26 | |||||
3-Year FCF Growth Rate | -23.6 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 29.72 | |||||
9-Day RSI | 31.62 | |||||
14-Day RSI | 34.85 | |||||
12-1 Month Momentum % | -54.84 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.05 | |||||
Quick Ratio | 0.03 | |||||
Days Inventory | 245.61 | |||||
Days Sales Outstanding | 51.97 | |||||
Days Payable | 725.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -5.8 | |||||
Shareholder Yield % | -366.94 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 53.51 | |||||
Operating Margin % | -601.94 | |||||
Net Margin % | -647.94 | |||||
FCF Margin % | -605.4 | |||||
ROA % | -256.47 | |||||
ROIC % | -44.58 | |||||
ROC (Joel Greenblatt) % | -396.08 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 2.5 | |||||
EV-to-EBIT | -2.93 | |||||
EV-to-EBITDA | -3.1 | |||||
EV-to-Revenue | 17.38 | |||||
EV-to-FCF | -2.9 | |||||
Earnings Yield (Greenblatt) % | -34.13 | |||||
FCF Yield % | -373.91 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Aequus Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.278 | ||
EPS (TTM) (€) | -0.017 | ||
Beta | 1.5 | ||
Volatility % | 292.43 | ||
14-Day RSI | 34.85 | ||
14-Day ATR (€) | 0.000229 | ||
20-Day SMA (€) | 0.003625 | ||
12-1 Month Momentum % | -54.84 | ||
52-Week Range (€) | 0.0005 - 0.0295 | ||
Shares Outstanding (Mil) | 132.63 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Aequus Pharmaceuticals Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Aequus Pharmaceuticals Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Aequus Pharmaceuticals Inc Frequently Asked Questions
What is Aequus Pharmaceuticals Inc(FRA:AEQ)'s stock price today?
When is next earnings date of Aequus Pharmaceuticals Inc(FRA:AEQ)?
Does Aequus Pharmaceuticals Inc(FRA:AEQ) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |